Breaking News

Piramal Pharma Solutions Expands & Upgrades UK Facilities

£55 million investment includes a multipurpose ADC manufacturing and aseptic fill/finish facility in Grangemouth and enhanced API manufacturing in Morpeth.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Piramal Pharma Solutions is expanding its Antibody-Drug Conjugate (ADC) capabilities at its Grangemouth facility in Scotland and is investing in new Active Pharmaceutical Ingredient (API) infrastructure at its Morpeth facility in England. The expansions and upgrades represent a total investment of approximately £55 million in the company’s UK-based drug development and manufacturing capabilities as well as new employment opportunities for technical and operational staff.   Grangemouth Site ADC...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters